Caricamento...

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Holmström, Morten Orebo, Hasselbalch, Hans Carl, Andersen, Mads Hald
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2017
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5674967/
https://ncbi.nlm.nih.gov/pubmed/29147619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1358334
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !